{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T21:56:34Z","timestamp":1759960594887},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":5314,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1992,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The levels of soluble interleukin\u20102 receptors (sIL\u20102R) were determined in the serum of 53 patients with B\u2010cell lymphoproliferative malignancies, including 31 patients with non\u2010Hodgkin lymphomas (NHL), 16 with chronic lymphocytic leukemia (CLL), and 6 with multiple myeloma. In addition, serum samples from 40 patients with various solid tumors as well as from 53 healthy individuals were used as controls. It was found that the mean serum levels of sIL\u20102R were significantly increased (<jats:italic>P<\/jats:italic> &lt; 0.001) in NHL (mean \u00b1 standard error of the mean 2,327 \u00b1 320 units\/ml) and CLL patients (2517 \u00b1 451 units\/ml) as compared to normal controls (207 \u00b1 17 units\/ml). No such difference was observed when the serum sIL\u20102R levels of patients with multiple myeloma or solid tumors were analyzed. Serum sIL\u20102R levels were closely related to the clinical stage, the presence of B\u2010symptoms, and the disease activity of patients with NHL and CLL. In fact, response to chemotherapy was followed by marked decrease or normalization of sIL\u20102R levels, while in a number of patients sIL\u20102R values were even able to predict disease relapse. Finally, no association with histologic grade in NHL patients, could be demonstrated.<\/jats:p><jats:p>We conclude that serum sIL\u20102R (1) are increased only in B\u2010NHL and B\u2010CLL but not in myeloma patients, (2) are related to the tumor burden, and (3) can serve as a valuable tumor marker for the monitoring of patients treatment.<\/jats:p>","DOI":"10.1002\/mpo.2950200106","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T18:23:01Z","timestamp":1171995781000},"page":"26-31","source":"Crossref","is-referenced-by-count":23,"title":["Serum\u2010soluble interleukin\u20102 receptors in B\u2010cell lymphoproliferative malignancies"],"prefix":"10.1002","volume":"20","author":[{"given":"Nicholas A.","family":"Pavlidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menelaus N.","family":"Manoussakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George S.","family":"Germanidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralampos M.","family":"Moutsopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4049\/jimmunol.133.4.1691","article-title":"Augmented T\u2010cell growth factor receptor expression in HTLV\u20101 infected human leukemic T\u2010cells","volume":"133","author":"Depper JM","year":"1984","journal-title":"J Immunol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-4-274"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1987.83"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V70.3.624.624","article-title":"High serum interleukin\u20102 receptor levels are related to advanced disease and a poor outcome in childhood non\u2010Hodgkin's lymphoma","volume":"70","author":"Pui CH","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V70.2.396.396","article-title":"High serum levels of soluble interleukin\u20102 receptor in patients with B\u2010chronic lymphocytic leukemia","volume":"70","author":"Semenzato G","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.8.1262"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.58.070189.004303"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3131876"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.126.4.1393","article-title":"A monoclonal antibody (anti\u2010Tac) reactive with activated and functionally mature T\u2010cells. I. Production of anti\u2010Tac monoclonal antibody and distribution of Tac (+) cells","volume":"126","author":"Uchiyama T","year":"1981","journal-title":"J Immunol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.1985.4.91"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(89)90140-2"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3095922"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.24.9694"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/172460088600100208","article-title":"Detection of a soluble form of the receptor for interleukin\u20102 in the serum of patients with hairy cell leukemia","volume":"1","author":"Chilosi M","year":"1986","journal-title":"Int J Biol Markers"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-4-560"},{"key":"e_1_2_1_17_2","first-page":"167","article-title":"Serum B2\u2010microglobulin in the assessment of lymphoid neoplasia: A review","volume":"2","author":"Cooper EH","year":"1981","journal-title":"Tumor Diagnost"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800701)46:1<139::AID-CNCR2820460122>3.0.CO;2-8"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950200106","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950200106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T13:39:56Z","timestamp":1698068396000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950200106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1992,1]]}},"alternative-id":["10.1002\/mpo.2950200106"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950200106","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,1]]}}}